X4 Pharmaceuticals

112 articles with X4 Pharmaceuticals

• X4 Pharma Announces New Data For Lead Candidate X4P-001 In Renal Cell Carcinoma At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium

  11/30/2016

• X4 Pharma Appoints Nancy Lurker As Chair Of Board Of Directors

  10/5/2016

• X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma

  9/27/2016

• X4 Pharma To Present At The 23rd Annual Biocentury Newsmakers In The Biotech Industry Conference

  9/7/2016

• X4 Pharma To Present At Canaccord Genuity’s 36th Annual Growth Conference

  8/8/2016

• X4 Pharma Appoints John K. Celebi As Chief Operating Officer

  6/13/2016

• X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma

  5/9/2016

• X4 Pharma Announces Data Presentation For Lead Candidate X4P-001 At AACR Annual Meeting

  4/20/2016

• X4 Pharma Announces Formation Of Corporate Advisory Board

  4/4/2016

• X4 Pharma Uses $37.5 Million to Push Cancer Therapies into Human Trials

  12/15/2015

• X4 Pharma Announces FDA Allowance Of X4P-001 IND For Phase 1b/2a Study Of In Refractory Clear Cell Renal Cell Carcinoma

  12/14/2015

• X4 Pharma Bags $37.5 Million in Funding, Backed by Former Genzyme Execs

  9/3/2015